University of California

Massachusetts Eye and Ear Infirmary

Eicosis, LLC

Hammock, Bruce D.

Lee, Kin Sing Stephen

Connor, Kip M.

Hasegawa, Eiichi

Kin Sing Stephen Lee

Bruce D Hammock

Ahmet Bora Inceoglu

Kip M Connor

Eiichi Hasegawa

This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).

Stable analogs of CYP450 lipid metabolites and inhibitors of soluble epoxide hydrolase

The invention discloses a new series of inhibitors of soluble epoxide hydrolase (sEH) with improved physical properties that enhance their druglikeness to treat sEH associated diseases such as chronic diabetic neuropathic pain.

Potent soluble epdxide hydrolase inhibitors

Growing community of inventors

Davis, CA, United States of America

Kin Sing Stephen Lee